 This is a Phase III, open-label, randomized, controlled, international study. Approximately 225 patients 82 years of age with MDS classified as RAEB-1, RAEB-2, or RAEB-t who received AZA or DAC for 9 months andor 9 cycles over 12 months and had their last dose of AZA or DAC within 6 months prior to screening will be stratified by: 